Literature DB >> 12761636

Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a therapy approaching evidence-based standards.

G Deuschl1, R Wenzelburger, F Kopper, J Volkmann.   

Abstract

DBS of the STN is one of the most promising new therapies for the treatment of PD. However - like many other therapies for PD - the present stage of the scientific assessment does not yet suffice the rigid criteria of evidence-based medicine. Further studies should specifically address the questions of efficacy and side effects as well as the impact on quality of life.

Entities:  

Mesh：

Year:  2003        PMID： 12761636     DOI： 10.1007/s00415-003-1109-8

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  14 in total

Review 1.  [Neuroethics--a future discipline?].

Authors:  G Northoff; J Witzel; B Bogerts
Journal:  Nervenarzt       Date:  2006-01       Impact factor: 1.214

2.  Clinical accuracy of a customized stereotactic platform for deep brain stimulation after accounting for brain shift.

Authors:  Pierre-François D'Haese; Srivatsan Pallavaram; Peter E Konrad; Joseph Neimat; J Michael Fitzpatrick; Benoit M Dawant
Journal:  Stereotact Funct Neurosurg       Date:  2010-01-05       Impact factor: 1.875

3.  The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease.

Authors:  Elizabeth L Birchall; Harrison C Walker; Gary Cutter; Stephanie Guthrie; Allen Joop; Raima A Memon; Ray L Watts; David G Standaert; Amy W Amara
Journal:  Brain Stimul       Date:  2016-12-27       Impact factor: 8.955

4.  Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease.

Authors:  Amy W Amara; David G Standaert; Stephanie Guthrie; Gary Cutter; Ray L Watts; Harrison C Walker
Journal:  Parkinsonism Relat Disord       Date:  2011-09-15       Impact factor: 4.891

5.  Activation of subthalamic neurons by contralateral subthalamic deep brain stimulation in Parkinson disease.

Authors:  Harrison C Walker; Ray L Watts; Christian J Schrandt; He Huang; Stephanie L Guthrie; Barton L Guthrie; Erwin B Montgomery
Journal:  J Neurophysiol       Date:  2010-12-22       Impact factor: 2.714

Review 6.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 7.  Advances in the treatment of depression.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  NeuroRx       Date:  2006-01

8.  Accuracy evaluation of microTargeting Platforms for deep-brain stimulation using virtual targets.

Authors:  Ramya Balachandran; Jason E Mitchell; Benoit M Dawant; J Michael Fitzpatrick
Journal:  IEEE Trans Biomed Eng       Date:  2009-01       Impact factor: 4.538

9.  Clinical testing of an alternate method of inserting bone-implanted fiducial markers.

Authors:  Ramya Balachandran; Mark A Fritz; Mary S Dietrich; Andrei Danilchenko; Jason E Mitchell; Veronica L Oldfield; Wendy W Lipscomb; J Michael Fitzpatrick; Joseph S Neimat; Peter E Konrad; Robert F Labadie
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-02-04       Impact factor: 2.924

10.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.